Thrombosis

Thrombosis / 2011 / Article / Tab 1

Research Article

The Use of a Scoring System to Guide Thromboprophylaxis in a High-Risk Pregnant Population

Table 1

Anticoagulation recommendations published in the BJOG, August 1999 [21].

Very high risk
Previous VTE while taking anticoagulantsThromboprophylaxis with dose adjusted for anti-Xa activity throughout pregnancy and for 12 weeks postpartum.
VTE in the current pregnancy
Antithrombin deficiency

High risk
Previous VTE while not on anticoagulantsFixed dose of LMWH from 24 weeks, earlier if additional risk factors for VTE. With previous pregnancy associated VTE, start 4–6 weeks ahead of gestation of the previous event and continue for 12 weeks postpartum.
Protein C deficiency and FMH
Homozygous Factor V Leiden
Homozygous prothrombin gene mutation
Combined thrombophilias

Moderate risk
Heterozygous factor V LeidenPostpartum LMWH prophylaxis for 6 weeks.
Heterozygous prothrombin gene mutation
Heterozygous protein S deficiency
FMH alone

Relatively low risk
Heterozygous Factor V Leiden with no FMHMonitor for additional risks.
Heterozygous PT gene mutation with no FMH

VTE: venous thromboembolism, LMWH: low molecular weight heparin, FMH: family history of VTE.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.